FDA Committee Supports Selzentry For Use In Treatment-Naïve Patients
On October 8, the Antiviral Drugs Advisory Committee of the Food and Drug Administration (FDA) recommended approval of Selzentry (maraviroc) for use in treatment-naïve patients. The Committee voted 10-4 in favor of extending Selzentry’s use to newly diagnosed individuals, but the FDA has yet to grant official approval.
Selzentry was originally approved for treatment-experienced patients in 2007. Pfizer, Selzentry’s manufacturer, applied for its expanded use in September after receiving results from study 1026.
Study 1026 compared a 300 mg dose of Selzentry given twice daily in combination with Combivir (zidovudine/lamivudine) to treatment of Combivir and Sustiva (efavirenz) in treatment-naïve patients. Sustiva is an effective antiretroviral already approved as an option for patients undergoing treatment for the first time.
Selzentry specifically targets HIV strains that use a protein, called CCR5, to enter human T cells. Other strains of HIV use the CXCR4 protein and are not susceptible to the effects of Selzentry. It has been suggested that treatment-naïve patients are the most appropriate group to receive Selzentry because most are infected with CCR5-using HIV only.
Pfizer initially applied for Selzentry approval after week 48 results became available from study 1026. The reviewing FDA committee determined that the results showed a significant rate of virologic failure, or reemergence of a high viral load, observed in participants taking Selzentry. As a result, the committee recommended waiting for the completion of the study at week 96 to monitor the long-term changes in viral load. These results are considered to be a more accurate assessment of the efficacy of Selzentry use in treatment-naive patients and are included in Pfizer’s recent application.
A more sensitive test to determine the type of protein, CCR5 or CXCR4, used by a patient’s HIV strain was developed during the course of the study. This test established that 44 percent of the virological failures seen were due to improper administration to individuals infected with CXCR4-using HIV.
The results from week 96 indicated that Selzentry was both safe and effective as a first-line treatment. Participants taking Selzentry showed similar changes in viral load and CD4 cell counts to those taking Sustiva. The Antiviral Drugs Advisory Committee has now voted to recommend approval of Selzentry for use in treatment-naïve patients.
For more information, please read the Antiretroviral Drugs Advisory Committee Briefing Document available on the FDA Web site, as well as the press release on the Pfizer Web site.
Related Articles:
- Study Shows Isentress Is As Effective As Sustiva For First-Line Treatment Of HIV
- “Quad” Regimen For HIV Treatment Shows Promising Results
- Tesamorelin Clinical Trial Reports Successful Reduction Of Fat Accumulation In HIV Patients
- AIDS Healthcare Foundation Urges Merck To Reduce Price On Anti-HIV Drug, Isentress
- Early Antiretroviral Therapy Slows Down Progression Of AIDS In Certain Individuals
THE CURE for HIV/AIDS…….AMBUSH
THE IDEA that AMBUSH cures AIDS
is being proven by the more than 400 individuals who have taken a dose of 60 ml three times daily for 21 days. The result is that AMBUSH ‘KILLS’ the virus by causing the protein envelope to rupture and the viral particles are discarded by the white blood cells. AMBUSH is able to ‘KILL’ the virus that are ‘hiding’ in the lymph system by its ‘natural radioactive’ properties. This process allows the body to ‘return to normal health’ with a corresponding immunity to that or those strains of the virus.
What is AMBUSH ?
AMBUSH is a radioactive isotope of uranium that is found in the ‘palm’ plant of which there are more than 3000 species. When ingested, AMBUSH causes the body temperature in the trunk area to rise to about 102 degrees when the individual is sleeping. The preparation takes four hours per batch, which is then given to the individuals for consumption 60 ml three times daily for 21 days. AMBUSH is a herbal preparation in this form but it contains an active ingredient which is a ‘NEW’ crystalline substance, a drug from the ‘palm plant’ similarly to ASPIRIN originating from the willow tree bark…
http://www.prlog.org/10095879-cure-for-hivaidsambush.html
Mishe posts his videos all over the web, but when contacted, he refuses to share any further information.
If you are going to post the info, then respond to inquiries.
Prise the lord, respected sir,Iam hiv+ detected on August08. my CD4 is 256 on February09. Iam using VIRADAY (CIPLA).kindly help me.AMBUSH how i get. Iam from Hyderabad, INDIA. Thankyou and regards.
Leave a comment
News
Resources
Links
Most Recent Comments
Subscribe
News Archives